InsidersTradesSigma
Total declarations
Companies
▲ Purchases (9 ops.)
▼ Sales (1 ops.)
Insider track record
OtherDisclosed buys
9
Disclosed sells
1
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Signal history
Discover the detailed record of transactions filed by Zakrzewski Joseph S. Officer active across 5 companies, notably Cyteir Therapeutics, Inc.. Cumulatively, 18 filings have been published. Breakdown: 9 buys · 1 sell. Total volume traded: €1.9m. Activity tracked since 15 December 2021. The latest transaction was disclosed on 14 August 2026 (Don). Regulator: SEC (Form 4). All data is free.
Companies and markets linked to Zakrzewski Joseph S
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations18 total
405,880 shares0Common StockSEC:0001193125-26-351801:0
10,523 shares0Common StockSEC:0000950170-25-053373:0
9,816 shares0Common StockSEC:0000950170-24-139793:0
2,000 shares@ US$1.400.2% of flowCommon StockSEC:0000950170-24-131499:0
Canonical exit: 25 Feb 2025 (T+90)
20,000 shares@ US$0.99981.1% of flowCommon StockSEC:0000950170-24-129248:0
Canonical exit: 16 Feb 2025 (T+90)
14,150 shares@ US$1.6912.2% of flowCommon StockSEC:0001209191-24-002992:0
100,000 shares@ US$19.114198.8% of flowCommon StockSEC:0000950170-24-005900:0
21,202 shares@ US$1.3014.4% of flowCommon StockSEC:0001209191-22-060377:0
Canonical exit: 7 Mar 2023 (T+90)
743 shares@ US$1.610.7% of flowCommon StockSEC:0001209191-22-029135:0
Canonical exit: 10 Aug 2022 (T+90)
49,406 shares@ US$1.8955.2% of flowCommon StockSEC:0001209191-22-028574:0
Canonical exit: 8 Aug 2022 (T+90)
98,199 sharesCommon StockSEC:0000899243-22-012992:0
12,500 shares0Common StockSEC:0001209191-22-014161:0
200 shares@ US$9.871.1% of flowCommon StockSEC:0000899243-21-049973:0
Canonical exit: 23 Mar 2022 (T+90)
200 shares@ US$9.881.1% of flowCommon StockSEC:0000899243-21-049198:0
Canonical exit: 17 Mar 2022 (T+90)
10,000 shares@ US$3.2689100.0% of flowOrdinary SharesSEC:0001562180-21-007737:0
Canonical exit: 14 Mar 2022 (T+90)
2,000 shares@ US$10.4711.6% of flowCommon StockSEC:0000899243-21-048432:0
Canonical exit: 15 Mar 2022 (T+90)
34,499 sharesCommon StockSEC:0001104659-21-142280:0
58,671 sharesCommon StockSEC:0000899243-21-025827:0
18 of 18 declarations
About Zakrzewski Joseph S
Zakrzewski Joseph S is a declarant and a Director at Cyteir Therapeutics, Inc., AN2 Therapeutics, Inc., Sangamo Therapeutics, INC, Amarin CORP Plc\uk and Acceleron Pharma INC. Across 17 filings in total, the recent filings reviewed run from 2021-06-24 to 2025-04-11, with EUR 188831 of buys and EUR 1755879 of sells; the most frequent transaction nature is Acquisition.
